Kolexia
Maillard Emmanuel Gastro-entérologie
Maillard Emmanuel
Gastro-entérologie
Centre Hospitalier Annecy Genevois
Epagny Metz-Tessy, France
49 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Adénocarcinome Métastase tumorale Tumeurs de l'oesophage Tumeurs du côlon Carcinomes Carcinome hépatocellulaire Tumeurs du rectum Récidive tumorale locale

Collaborateurs

Voir plus
Bedenne Laurent
Bedenne Laurent
Sncf Mobilites, Paris, France
Aparicio Thomas
Aparicio Thomas
Hôpital Avicenne, Bobigny, France
Baconnier Mathieu
Baconnier Mathieu
Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France
Bouche Olivier
Bouche Olivier
Hôpital Robert-Debré Reims, Reims, France

Industries

Voir plus
Sanofi
1 collaboration(s)
Dernière en 2022
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
PROFILER: Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Essai Clinique (Centre Léon-Bérard)   01 mars 2024
Dos caminos - Sor Emmanuel Maillard
Youtube @ Parroquia Sto. Cristo del Calvario Marbella   17 septembre 2022
390P Impact of age on treatment strategies in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): A prespecified subgroup analysis of the GERCOR-PRODIGE STRATEGIC-1 phase III study
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study.
2022 ASCO Annual Meeting I   02 juin 2022
MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma FNCLCC-FFCD-AGEO PRODIGE 17-ACCORD 20 Randomized Phase II Trial
Essai Clinique (Unicancer)   13 novembre 2020
Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLD.
Journal of geriatric oncology   22 avril 2020
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.
Annals of oncology : official journal of the European Society for Medical Oncology   07 avril 2020
Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer: Randomized Study of Pre-Operative Radio-Chemotherapy Versus Surgery Alone in Thoracic Esophageal Cancer Deemed to be Resectable
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   27 mars 2020
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.
Annals of oncology : official journal of the European Society for Medical Oncology   03 avril 2019
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trial
Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8-12 September 2017, Madrid, Spain   01 septembre 2017